Why the study?
The study was designed to evaluate the long-term clinical performance and efficacy of a novel sirolimus-coated balloon for treating de novo coronary lesions and in-stent restenosis.
Does a sirolimus-coated balloon prevent major adverse cardiovascular events in patients with de novo coronary lesions or in-stent restenosis?
Does a sirolimus-coated balloon prevent major adverse cardiovascular events in patients with de novo coronary lesions or in-stent restenosis?
The use of a novel sirolimus-coated balloon for de novo coronary lesions and in-stent restenosis demonstrated safety and feasibility with a low MACE rate of 4.2% at 24 months.
Answers are grounded in this paper and cite their sources.
Low 24-month MACE supports SCB feasibility in real-world lesions; leaves open randomized trials versus paclitaxel-coated balloons.
OBJECTIVES: To test the long-term efficacy of a sirolimus-coated balloon (SCB). BACKGROUND: Nanoluté was a prospective registry to evaluate the clinical performance of a novel SCB (Concept Medical Research Private Limited, India) for the treatment of de novo coronary lesions and in-stent restenosis (ISR). We here present the 24 months clinical data. METHODS: All patients treated with SCB for any type of coronary indication between July 2012 and September 2015 were enrolled at Indian centers and clinically followed up to 24 months. Primary endpoints were major adverse cardiovascular events (MACE) defined as a composite of cardiac death, target lesion revascularization (TLR), and target vessel-myocardial infarction (MI). RESULTS: A total of 484 SCBs were used in 408 patients to treat 435 lesions. In detail, the SCB was used for 183 patients with ISR, 185 with de novo small vessel disease, and 40 with de novo large vessel disease. Mean balloon length and diameter (average ± SD) were 22.3 ± 7.1 mm and 2.7 ± 0.40 mm, respectively. All patients with 24 months follow-up were included. Overall MACE rate was 4.2% (n = 17) with three cardiac deaths (0.7%), 13 TLR (3.2%), and one MI (0.2%). CONCLUSION: The Nanoluté prospective registry is the first long-term clinical evidence of the safety and feasibility of this type of SCB, both in patients with ISR or de novo lesions.
No takes yet. Share an insight, caveat, or question.
El‐Mokdad et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: